Effects of exenatide (Byetta) on liver biochemistry, liver histology and lipid metabolism in patients with non-alcoholic fatty liver disease
Phase of Trial: Phase II
Latest Information Update: 23 Jun 2017
At a glance
- Drugs Exenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- 31 Aug 2018 Biomarkers information updated
- 01 Feb 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 20 Jul 2008 The expected completion date for this trial has been extended from Jun 2009 to Feb 2010 as reported by ClinicalTrials.gov.